Micron expects fiscal Q1 revenue of $61.5B ±$1.5B as it raises fiscal 2027 CapEx plans amid tighter 2027-2028 supply-demand (NASDAQ:MU)October 1, 2026
Bristol Myers schizophrenia therapy safe in late-stage trial Markets April 6, 2024 hapabapa/iStock Editorial through Getty Pictures Bristol Myers Squibb (NYSE:BMY) introduced Saturday that its experimental schizophrenia remedy KarXT, acquired as a…
